Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean category antidepressive agent an group approved?
Displaying drugs 10101 - 10125 of 10303 in total

5'-O-(N-(Alanyl)sulfamoyl)adenosine

Experimental

CHROMOPHORE (ASP-TYR-GLY)

Experimental

Meclinertant

Investigational

2-HYDROXY-5-{[(1E)-2-PHENYLETHYLIDENE]AMINO}-L-TYROSINE

Experimental

N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE

Experimental

5'-ACETYL-4-{[(2,4-DIMETHYLPHENYL)SULFONYL]AMINO}-2,2'-BITHIOPHENE-5-CARBOXYLIC ACID

Experimental

Tesetaxel

Tesetaxel has been used in trials studying the treatment of Cancer, Melanoma, Prostate Cancer, Gastric Carcinoma, and Advanced Melanoma, among others.
Investigational

BMS-777607

BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.
Investigational

Defactinib

Defactinib has been investigated for the treatment of Malignant Pleural Mesothelioma.
Investigational

CEP-37440

CEP-37440 has been used in trials studying the treatment of Solid Tumors.
Investigational

Chiniofon

Experimental

Calcium pangamate

Experimental

AZD-9496

AZD-9496 is under investigation in clinical trial NCT02248090 (AZD9496 First Time in Patients Ascending Dose Study).
Investigational

N-[O-Phosphono-Pyridoxyl]-Isoleucine

Experimental

Vitamin B6 Complexed with 2-Amino-Pentanoic Acid

Experimental

3-(4-Amino-2-Tert-Butyl-5-Methyl-Phenylsulfanyl)-6-Cyclopentyl-4-Hydroxy-6-[2-(4-Hydroxy-Phenyl)-Ethyl]-5,6-Dihydro-Pyran-2-One

Experimental

2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID

Experimental

4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide

Experimental

(4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile

Experimental

(S)-Indapamide

Experimental

N-((1R,2S)-2-(5-CHLORO-1H-INDOLE-2-CARBOXAMIDO)CYCLOHEXYL)-5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXAMIDE

Experimental

AT-7519

AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.
Investigational

(4R)-7-chloro-9-methyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile

Experimental

5-bromo-3-(pyrrolidin-1-ylsulfonyl)-1H-indole-2-carboxamide

Experimental

4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE

Experimental
Displaying drugs 10101 - 10125 of 10303 in total